Sharon Shacham

Sharon Shacham

UNVERIFIED PROFILE

Are you Sharon Shacham?   Register this Author

Register author
Sharon Shacham

Sharon Shacham

Publications by authors named "Sharon Shacham"

Are you Sharon Shacham?   Register this Author

89Publications

2413Reads

24Profile Views

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

N Engl J Med 2019 08;381(8):727-738

From the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai (A.C., S.P., S.J.), and New York University Langone Medical Center (D.K.) - both in New York; the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia (D.T.V.); the School of Medicine, National and Kapodistrian University of Athens, Athens (M.G., M. Dimopoulos); the Winship Cancer Institute, Emory University, Atlanta (A.K.N., S.L.); Massachusetts General Hospital Cancer Center (A.J.Y.), Tufts Medical Center (R.L.C.), and the Dana-Farber Cancer Institute (P.G.R.), Boston, and Karyopharm Therapeutics, Newton (M.G.K., S.S., L.L., S. Tang, C.P., J.-R.S.-M., M.C., H.C., Y.L., J.S.) - all in Massachusetts; Johns Hopkins University, Baltimore (C.A.H.); the University of Nantes, Nantes (P.M.), Hôpital Necker (L.F.), Hôpital Saint-Antoine (M.M.), and La Pitié-Salpêtrière Hospital (S.C.), Paris, University Hospital, Lille (T.F.), Centre Hospitalier Lyon Sud, Pierre-Benite (L.K.), and Centre Hospitalo-Universitaire Vandoeuvre-lès-Nancy, Nancy (A.P.) - all in France; the Mayo Clinic, Rochester, MN (D.D.); the University of Michigan, Ann Arbor (C.C.); the Mayo Clinic of Arizona, Phoenix (A.K.S.); Hackensack University Medical Center, Hackensack, NJ (J.R.); Washington University School of Medicine, St. Louis (R.V.); Lineberger Comprehensive Cancer Center at University of North Carolina-Chapel Hill, Chapel Hill (S. Tuchman); the University of Heidelberg, Heidelberg (M.S.R.), University Medical Center Hamburg-Eppendorf, Hamburg (K.C.W.), the University of Tübingen, Tübingen (K.C.W.), University Hospital Würzburg, Würzburg (M.S.), the University of Freiburg, Freiburg (M.E.), and Gemeinschaftspraxis Hämatologie-Onkologie, Dresden (T.I.) - all in Germany; the University of Leuven, Leuven (M. Delforge), Institut Jules Bordet, Université Libre de Bruxelles, Brussels (N.M.), University Hospital Ghent, Ghent (P.V.), and Centre Hospitalier Universitaire Université Catholique de Louvain Namur, Yvoir (C.D.) - all in Belgium; Vanderbilt University Medical Center, Nashville (R.F.C.); Sylvester Cancer Center, University of Miami, Miami (J.E.H.); the University of Alabama at Birmingham, Birmingham (L.J.C.); Yale School of Medicine, New Haven, CT (T.L.P.); Baylor University Medical Center, Dallas (M.L.); the David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (G.S.); and University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria (K.P.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1903455
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1903455DOI Listing
August 2019

In vitro toxicity and efficacy of verdinexor, an exportin 1 inhibitor, on opportunistic viruses affecting immunocompromised individuals.

PLoS One 2018 17;13(10):e0200043. Epub 2018 Oct 17.

Karyopharm Therapeutics, Department of Neurofegenerative and Infectious Diseases, Newton, Massachussets, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0200043PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192554PMC
March 2019

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.

J Clin Oncol 2018 03 30;36(9):859-866. Epub 2018 Jan 30.

Dan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.5207DOI Listing
March 2018

Antiviral Efficacy of Verdinexor In Vivo in Two Animal Models of Influenza A Virus Infection.

PLoS One 2016 28;11(11):e0167221. Epub 2016 Nov 28.

Department of Infectious Diseases, University of Georgia College of Veterinary Medicine, Athens, Georgia, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0167221PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125695PMC
August 2017

The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.

Clin Cancer Res 2017 May 25;23(10):2528-2541. Epub 2016 Oct 25.

KU Leuven Department of Microbiology and Immunology, Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-1580DOI Listing
May 2017

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors.

J Clin Oncol 2016 12 31;34(34):4142-4150. Epub 2016 Oct 31.

Albiruni R. Abdul Razak and Lee-Anne Stayner, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Morten Mau-Soerensen and Ulrik Lassen, Rigshospitalet, Copenhagen, Denmark; Nashat Y. Gabrail, Gabrail Cancer Institute, Canton, OH; John F. Gerecitano, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, NY; Anthony F. Shields, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Thaddeus J. Unger, Jean R. Saint-Martin, Robert Carlson, Yosef Landesman, Dilara McCauley, Tami Rashal, Mansoor R. Mirza, Michael Kauffman, and Sharon Shacham, Karyopharm Therapeutics, Newton, MA; and Richard Kim and Amit Mahipal, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.3949DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562433PMC
December 2016

XPO1 Inhibition Preferentially Disrupts the 3D Nuclear Organization of Telomeres in Tumor Cells.

J Cell Physiol 2016 12 8;231(12):2711-9. Epub 2016 Apr 8.

Manitoba Institute of Cell Biology, CancerCare Manitoba, University of Manitoba, Winnipeg, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.25378DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111786PMC
December 2016

Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export.

Oncotarget 2016 Oct;7(42):68842-68850

Katholieke Universiteit Leuven, Department of Immunology and Microbiology, Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.11995DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356594PMC
October 2016

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.

J Clin Oncol 2016 09 25;34(26):3166-74. Epub 2016 Jul 25.

Mrinal M. Gounder, William D. Tap, Mark A. Dickson, Mary Louise Keohan, Sandra P. D'Angelo, Mercedes Condy, Lanier Tanner, Joseph P. Erinjeri, and Francis H. Jasmine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College; Gary K. Schwartz, Columbia University Medical Center, New York, NY; Alona Zer, Samer Salah, Abha A. Gupta, Herbert H. Loong, Stephanie Baker, Kjirsten Nyquist-Schultz, and Albiruni Ryan Abdul Razak, Princess Margaret Cancer Center, Toronto, Ontario, Canada; and Sharon Friedlander, Robert Carlson, Thaddeus J. Unger, Jean-Richard Saint-Martin, Tami Rashal, Joel Ellis, Michael Kauffman, and Sharon Shacham, Karyopharm Therapeutics, Newton, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.6346DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321073PMC
September 2016

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.

J Hematol Oncol 2016 08 24;9(1):73. Epub 2016 Aug 24.

Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-016-0304-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997728PMC
August 2016

CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling.

Cancer Res 2016 05 8;76(9):2687-97. Epub 2016 Mar 8.

Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California. Cancer Science Institute of Singapore, National University of Singapore, Singapore. National University Cancer Institute, National University Hospital Singapore, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-1572DOI Listing
May 2016

XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer.

Clin Cancer Res 2016 Apr 24;22(7):1663-73. Epub 2015 Nov 24.

Division of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0978DOI Listing
April 2016

A Nuclear Attack on Traumatic Brain Injury: Sequestration of Cell Death in the Nucleus.

CNS Neurosci Ther 2016 Apr 4;22(4):306-15. Epub 2016 Feb 4.

Department of Neurosurgery and Brain Repair, University of South Florida Morsani College of Medicine, Tampa, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cns.12501DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067638PMC
April 2016

Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma.

EBioMedicine 2015 Sep 1;2(9):1102-13. Epub 2015 Aug 1.

KU Leuven, Department of Microbiology and Immunology, Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, B-3000 Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2015.07.041DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588406PMC
September 2015

Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth.

PLoS One 2014 2;9(12):e113867. Epub 2014 Dec 2.

Division of Nephrology, Dept. of Internal Medicine, University of California Davis, Davis, California, United States of America; Cancer Center, University of California Davis, Davis, California, United States of America; Medical Service, Sacramento VA Medical Center, Sacramento, California, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0113867PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4252068PMC
July 2015

XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.

Clin Cancer Res 2015 Jul 15;21(14):3286-97. Epub 2015 Apr 15.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Center for RNA Interference and Non-coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1953DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506247PMC
July 2015

Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.

Neuro Oncol 2015 May 2;17(5):697-707. Epub 2014 Nov 2.

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts (A.L.G., J.A.P., J.H.-R.H., B.H.-E.); Division of Hematology-Oncology, Boston Children's Hospital, Boston, Massachusetts (A.L.G.); Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.H.R., L.A.R., C.L.M., D.S.K., K.L.L.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.H.R., K.L.L.); Karyopharm Therapeutics, Natick, Massachusetts (D.M., S.S.); Lurie Family Imaging Center, Dana-Farber Cancer Institute, Boston, Massachusetts (K.J.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.); Department of Pediatrics, Columbia University Medical Center, New York, New York (A.L.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nou303DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482855PMC
May 2015

Nuclear export inhibitors avert progression in preclinical models of inflammatory demyelination.

Nat Neurosci 2015 Apr 23;18(4):511-20. Epub 2015 Feb 23.

1] Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, USA. [2] Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nn.3953DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522902PMC
April 2015

Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing.

Chem Biol 2015 Jan 8;22(1):107-16. Epub 2015 Jan 8.

Department of Microbiology and Immunology, Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, KU Leuven-University of Leuven, 3000 Leuven, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chembiol.2014.11.015DOI Listing
January 2015

Understanding XPO1 target networks using systems biology and mathematical modeling.

Curr Pharm Des 2014 ;20(1):56-65

Department of Biochemistry, Aligarh Muslim University, Aligarh, 202002, UP India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/13816128113199990611DOI Listing
September 2014

KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.

Cancer Chemother Pharmacol 2014 Sep 17;74(3):487-95. Epub 2014 Jul 17.

State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2495-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4146741PMC
September 2014

Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer.

Oncotarget 2014 Aug;5(15):6102-12

Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171616PMC
http://dx.doi.org/10.18632/oncotarget.2174DOI Listing
August 2014

Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.

BMC Vet Res 2014 Jul 15;10:160. Epub 2014 Jul 15.

Departments of Veterinary Biosciences and Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, 1925 Coffey Rd,, Columbus, OH 43210, USA.

View Article

Download full-text PDF

Source
http://bmcvetres.biomedcentral.com/articles/10.1186/1746-614
Publisher Site
http://dx.doi.org/10.1186/1746-6148-10-160DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105800PMC
July 2014

Genomic and molecular characterization of esophageal squamous cell carcinoma.

Nat Genet 2014 May 30;46(5):467-73. Epub 2014 Mar 30.

1] Cedars-Sinai Medical Center, Division of Hematology/Oncology, University of California Los Angeles School of Medicine, Los Angeles, California, USA. [2] Cancer Science Institute of Singapore, National University of Singapore, Singapore. [3] National University Cancer Institute, National University Hospital Singapore, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng.2935DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070589PMC
May 2014

XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer.

Mol Cancer Ther 2014 Mar 15;13(3):675-86. Epub 2014 Jan 15.

Corresponding Author: Rachel A. Altura, Department of Pediatrics, Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-13-0416DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3954411PMC
March 2014

CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo.

J Cancer 2013 10;4(8):614-25. Epub 2013 Sep 10.

1. Department of Blood and Marrow Transplantation and Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/jca.7080DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805989PMC
October 2013

Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas.

Haematologica 2013 Jul 12;98(7):1098-106. Epub 2013 Feb 12.

Department of Pathology, Wayne State University, Detroit MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2012.074781DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3696614PMC
July 2013

CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth.

J Urol 2013 Jun 16;189(6):2317-26. Epub 2012 Oct 16.

Division of Nephrology, Department of Internal Medicine, University of California-Davis, Davis, California 95616, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2012.10.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4593314PMC
June 2013

Prognostic impact and targeting of CRM1 in acute myeloid leukemia.

Blood 2013 May 5;121(20):4166-74. Epub 2013 Apr 5.

Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2012-08-447581DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656451PMC
May 2013

Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma.

Exp Hematol 2013 Jan 14;41(1):67-78.e4. Epub 2012 Sep 14.

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2012.09.002DOI Listing
January 2013

Consensus Induced Fit Docking (cIFD): methodology, validation, and application to the discovery of novel Crm1 inhibitors.

J Comput Aided Mol Des 2012 Nov 30;26(11):1217-28. Epub 2012 Sep 30.

Karyopharm Therapeutics, 2 Mercer Road, Natick, MA 01760, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10822-012-9611-9DOI Listing
November 2012

The effects of PRX-07034, a novel 5-HT6 antagonist, on cognitive flexibility and working memory in rats.

Psychopharmacology (Berl) 2012 Apr 12;220(4):687-96. Epub 2011 Oct 12.

Department of Psychology, University of Illinois at Chicago, 1007 West Harrison Street, Chicago, IL 60607, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00213-011-2518-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3636983PMC
April 2012

PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats.

J Pharmacol Exp Ther 2010 Aug 29;334(2):364-72. Epub 2010 Apr 29.

Department of Pediatrics, Powell Gene Therapy Center, University of Florida, Gainesville, Florida 32610-0266, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.109.165001DOI Listing
August 2010

Measurements of the static friction coefficient between bone and muscle tissues.

J Biomech Eng 2010 Aug;132(8):084502

Department of Biomedical Engineering, Faculty of Engineering, Tel Aviv University, Tel Aviv 69978, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1115/1.4001893DOI Listing
August 2010

PRX-00023, a selective serotonin 1A receptor agonist, reduces ultrasonic vocalizations in infant rats bred for high infantile anxiety.

Pharmacol Biochem Behav 2009 Nov 2;94(1):8-15. Epub 2009 Jul 2.

Division of Developmental Neuroscience, New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pbb.2009.06.014DOI Listing
November 2009

VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux.

Neuropharmacology 2007 Sep 30;53(4):563-73. Epub 2007 Jun 30.

Department of Psychology, University of Illinois at Chicago, Chicago, IL 60607, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuropharm.2007.06.016DOI Listing
September 2007

Identification of Ser153 in ICL2 of the gonadotropin-releasing hormone (GnRH) receptor as a phosphorylation-independent site for inhibition of Gq coupling.

J Biol Chem 2005 Aug 17;280(32):28981-8. Epub 2005 Jun 17.

Department of Biochemistry, George S. Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv 69978, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M500312200DOI Listing
August 2005

G protein-coupled receptors: in silico drug discovery in 3D.

Proc Natl Acad Sci U S A 2004 Aug 26;101(31):11304-9. Epub 2004 Jul 26.

Predix Pharmaceuticals, Ltd., S.A.P. Building, 3 Hayetzira Street, Ramat Gan 52521, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0401862101DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC509175PMC
August 2004

Modeling the 3D structure of GPCRs: advances and application to drug discovery.

Curr Opin Drug Discov Devel 2003 May;6(3):353-61

Predix Pharmaceuticals Ltd, SAP Building, 3 Hayetzira Street, Ramat Gan 52521, Israel.

View Article

Download full-text PDF

Source
May 2003